X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (31158) 31158
Book Review (1867) 1867
Publication (1856) 1856
Conference Proceeding (144) 144
Book Chapter (42) 42
Newsletter (29) 29
Paper (14) 14
Magazine Article (11) 11
Book / eBook (9) 9
Dissertation (7) 7
Government Document (4) 4
Web Resource (3) 3
Data Set (2) 2
Journal / eJournal (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (27188) 27188
humans (19539) 19539
doxorubicin (13883) 13883
doxorubicin - pharmacology (12935) 12935
animals (12661) 12661
pharmacology & pharmacy (9112) 9112
female (8840) 8840
oncology (7990) 7990
mice (6883) 6883
cancer (6836) 6836
male (6719) 6719
cell line, tumor (6233) 6233
chemotherapy (5690) 5690
doxorubicin - administration & dosage (5394) 5394
antineoplastic agents - pharmacology (5121) 5121
anthracyclines (4370) 4370
apoptosis (4232) 4232
rats (3668) 3668
antibiotics, antineoplastic - pharmacology (3472) 3472
cell survival - drug effects (3461) 3461
middle aged (3295) 3295
apoptosis - drug effects (3211) 3211
drug delivery systems (3199) 3199
nanoparticles (3120) 3120
adult (2814) 2814
biochemistry & molecular biology (2807) 2807
drugs (2777) 2777
antineoplastic combined chemotherapy protocols - therapeutic use (2716) 2716
dose-response relationship, drug (2674) 2674
adriamycin (2633) 2633
aged (2580) 2580
tumor cells, cultured (2564) 2564
doxorubicin - therapeutic use (2533) 2533
drug resistance (2473) 2473
expression (2469) 2469
breast neoplasms - drug therapy (2330) 2330
doxorubicin - chemistry (2306) 2306
in-vitro (2255) 2255
tumors (2219) 2219
cells (2135) 2135
therapy (2128) 2128
breast cancer (2071) 2071
drug resistance, neoplasm (2049) 2049
doxorubicin - toxicity (2042) 2042
chemistry, multidisciplinary (2038) 2038
doxorubicin - pharmacokinetics (2030) 2030
analysis (2023) 2023
p-glycoprotein (1887) 1887
cytotoxicity (1879) 1879
cell proliferation - drug effects (1828) 1828
toxicity (1811) 1811
cell biology (1729) 1729
drug-delivery (1679) 1679
doxorubicin - adverse effects (1678) 1678
liposomes (1669) 1669
vehicles (1630) 1630
cell line (1626) 1626
neoplasms - drug therapy (1603) 1603
doxorubicin - analogs & derivatives (1580) 1580
mice, inbred balb c (1575) 1575
time factors (1569) 1569
breast neoplasms - pathology (1566) 1566
multidrug-resistance (1544) 1544
in-vivo (1541) 1541
mice, nude (1540) 1540
research (1533) 1533
antineoplastic agents - therapeutic use (1528) 1528
drug synergism (1527) 1527
antineoplastic agents - administration & dosage (1526) 1526
doxorubicin - metabolism (1525) 1525
cardiotoxicity (1514) 1514
drug carriers - chemistry (1481) 1481
drug delivery (1446) 1446
multidrug resistance (1443) 1443
treatment outcome (1443) 1443
proteins (1432) 1432
care and treatment (1427) 1427
antibiotics, antineoplastic - administration & dosage (1405) 1405
breast-cancer (1403) 1403
antineoplastic agents - chemistry (1376) 1376
nanoparticles - chemistry (1355) 1355
oxidative stress (1353) 1353
pharmacokinetics (1346) 1346
paclitaxel (1345) 1345
medicine, research & experimental (1307) 1307
micelles (1302) 1302
chemistry, medicinal (1284) 1284
health aspects (1269) 1269
inhibition (1243) 1243
article (1224) 1224
cyclophosphamide - administration & dosage (1218) 1218
flow cytometry (1184) 1184
cells, cultured (1176) 1176
pharmacology/toxicology (1168) 1168
cancer therapies (1160) 1160
antineoplastic combined chemotherapy protocols - adverse effects (1159) 1159
cisplatin (1158) 1158
delivery (1150) 1150
drug therapy (1150) 1150
kinetics (1147) 1147
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (30114) 30114
Chinese (468) 468
Japanese (332) 332
Russian (138) 138
German (59) 59
French (50) 50
Italian (35) 35
Spanish (26) 26
Polish (12) 12
Ukrainian (11) 11
Croatian (4) 4
Czech (4) 4
Hungarian (3) 3
Portuguese (2) 2
Serbian (2) 2
Turkish (2) 2
Dutch (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Anti-Cancer Drugs, ISSN 0959-4973, 03/2013, Volume 24, Issue 3, pp. 251 - 259
Journal Article
Cancer Letters, ISSN 0304-3835, 2016, Volume 383, Issue 2, pp. 309 - 317
Abstract In previous studies we demonstrated that targeting the nuclear exporter protein exportin-1 (CRM1/XPO1) by a selective inhibitor of nuclear export... 
Hematology, Oncology and Palliative Medicine | NHL | XPO1 | Selective inhibitors of nuclear export | SINE | CRM1 | Exportin-1 | SURVIVAL | DRUG-RESISTANCE | MODEL | CANCER | STRATEGIES | ONCOLOGY | LINE | CHOP | PROTEINS | Vincristine - pharmacology | TOR Serine-Threonine Kinases - metabolism | Transcription Factor RelA - antagonists & inhibitors | Apoptosis - drug effects | Humans | Lymphoma, Non-Hodgkin - enzymology | Lymphoma, Non-Hodgkin - pathology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | TOR Serine-Threonine Kinases - antagonists & inhibitors | Dexamethasone - pharmacology | Time Factors | Oxadiazoles - pharmacology | Acrylamides - pharmacology | Lymphoma, Non-Hodgkin - drug therapy | Cell Survival - drug effects | Hydrazines - pharmacology | Everolimus - pharmacology | Mice, SCID | Mice, Inbred ICR | Drug Synergism | Triazoles - pharmacology | Xenograft Model Antitumor Assays | Animals | Karyopherins - metabolism | Signal Transduction - drug effects | Transcription Factor RelA - metabolism | Tumor Burden - drug effects | Active Transport, Cell Nucleus - drug effects | Cyclophosphamide - pharmacology | Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors | Cell Line, Tumor | Prednisone - pharmacology | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Karyopherins - antagonists & inhibitors | Doxorubicin - pharmacology | Receptors, Cytoplasmic and Nuclear - metabolism | International trade | Cyclophosphamide | Care and treatment | Dexamethasone | Analysis | Lymphomas | Prednisone | Exports | Steroids | Cancer | Drugs | TOR protein | Animal models | Laboratories | Toxicity | Xenotransplantation | Clinical trials | Cytotoxicity | Kinases | Experiments | Anticancer properties | Proteins | Cell growth | Antitumor agents | Cell cycle | Xenografts | Biocompatibility | Localization | Drug dosages | NF-κB protein | Chronic lymphatic leukemia | Hematology | Pharmacology | Chemical compounds | Patients | Lymphoma | Nuclear transport | Studies | Inhibitors | Response rates | In vivo methods and tests | Apoptosis | Index Medicus
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 8/2010, Volume 107, Issue 33, pp. 14621 - 14626
A bottleneck in drug discovery is the identification of the molecular targets of a compound (mode of action, MoA) and of its off-target effects. Previous... 
Community structure | Datasets | Communities | Genes | Cell lines | Antineoplastics | Signatures | Dosage | Gene expression | Mode of action | Drug repurposing | Chemotherapy | Systems biology | Computational drug discovery | systems biology | TARGET | NETWORK | computational drug discovery | MULTIDISCIPLINARY SCIENCES | CONNECTIVITY MAP | EXPRESSION PROFILES | KAPPA-B | AUTOPHAGY | chemotherapy | CANCER | CELL-DEATH | drug repurposing | CAMPTOTHECIN | DISEASE | Neoplasms - metabolism | Oligonucleotide Array Sequence Analysis | Humans | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - analogs & derivatives | Drug Discovery - methods | Gene Expression Profiling | RNA Polymerase II - metabolism | Autophagy - drug effects | Neoplasms - genetics | Piperidines - pharmacology | Antineoplastic Agents - pharmacology | Flavonoids - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Phosphorylation - drug effects | Antineoplastic Agents - classification | Fuzzy Logic | Camptothecin - analogs & derivatives | Pyrazoles - pharmacology | Drug Screening Assays, Antitumor - methods | Blotting, Western | Pyrroles - pharmacology | Algorithms | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - pharmacology | Cell Line, Tumor | HeLa Cells | Neoplasms - pathology | Camptothecin - pharmacology | Doxorubicin - pharmacology | Dose-response relationship (Biochemistry) | Physiological aspects | Research | Observations | Methods | Cancer | Pharmacology | Biochemistry | Kinases | Research & development--R&D | Index Medicus | Cyclin-dependent kinase 2 | Drugs | Enhancers | Neurodegenerative diseases | Transcription | Drug discovery | Nodes | Phagocytosis | Rho-associated kinase | Biological Sciences
Journal Article
International Journal of Cancer, ISSN 0020-7136, 03/2004, Volume 109, Issue 1, pp. 1 - 8
Heme oxygenase‐1 (HO‐1), an inducible enzyme that catalyzes oxidative degradation of heme to form biliverdin, carbon monoxide and free iron, may protect tumor... 
heme oxygenase‐1 | zinc protoporphyrin | macromolecular therapeutics | tumor targeting/EPR effect | D‐amino acid oxidase | Macromolecular therapeutics | D-amino acid oxidase | Tumor targeting/EPR effect | Heme oxygenase-1 | Zinc protoporphyrin | HUMAN BRAIN-TUMORS | CANCER-CHEMOTHERAPY | INDUCED APOPTOSIS | NITRIC-OXIDE SYNTHASE | heme oxygenase-1 | MACROMOLECULAR DRUGS | MESSENGER-RNA | ONCOLOGY | GENE-EXPRESSION | SOLID TUMOR | HYDROGEN-PEROXIDE PRODUCTION | TARGETED DELIVERY | Oxidants - pharmacology | Body Weight | Reactive Oxygen Species - metabolism | Oxidative Stress | Coloring Agents - pharmacology | Annexin A5 - pharmacology | Humans | Male | Metalloporphyrins - pharmacology | Oxygen - metabolism | Dose-Response Relationship, Drug | Antineoplastic Agents - pharmacology | Heme Oxygenase (Decyclizing) - antagonists & inhibitors | Polyethylene Glycols - pharmacology | Oxidation-Reduction | Hydrogen Peroxide - pharmacology | Etoposide - pharmacology | Tetrazolium Salts - pharmacology | Cisplatin - pharmacology | Hydrogen Peroxide - metabolism | Mitomycin - pharmacology | Neoplasms - drug therapy | Proline - chemistry | Drug Synergism | Animals | Cell Line, Tumor | Mice | Thiazoles - pharmacology | Antineoplastic Agents, Phytogenic - pharmacology | Camptothecin - pharmacology | Doxorubicin - pharmacology | Apoptosis | Index Medicus
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 10/2013, Volume 110, Issue 43, pp. 17253 - 17258
Phenotypic polarization of macrophages is regulated by a milieu of cues in the local tissue microenvironment. Although much is known about how soluble factors... 
Phenotypes | Cell growth | Cytokines | Stem cells | Cell lines | Actins | Physiological regulation | Macrophages | Endothelial cells | Cells | FIBER | MATRIX | ACTIVATION | ACTIN | MULTIDISCIPLINARY SCIENCES | IN-VIVO | DIFFERENTIATION | SCAFFOLDS | CULTURE | MESENCHYMAL STEM-CELLS | Mannose-Binding Lectins - metabolism | Arginase - metabolism | Lectins, C-Type - immunology | Cell Shape - immunology | Myosin-Light-Chain Kinase - antagonists & inhibitors | Cytochalasin D - pharmacology | Lectins, C-Type - metabolism | Arginase - immunology | Interleukin-4 - pharmacology | Flow Cytometry | Doxorubicin - analogs & derivatives | Inflammation Mediators - metabolism | Female | Immunophenotyping - methods | Cell Polarity - drug effects | Doxorubicin - metabolism | Macrophages - immunology | Cytokines - immunology | Amides - pharmacology | Biomarkers - metabolism | Inflammation Mediators - immunology | Cell Polarity - immunology | Cytokines - metabolism | Myosin-Light-Chain Kinase - metabolism | Mice, Inbred C57BL | Biomarkers - analysis | Cells, Cultured | Receptors, Cell Surface - metabolism | Macrophages - cytology | Interleukin-13 - pharmacology | Receptors, Cell Surface - immunology | Azepines - pharmacology | Cell Shape - drug effects | Macrophages - metabolism | Animals | Mannose-Binding Lectins - immunology | Lipopolysaccharides - pharmacology | Mice | Pyridines - pharmacology | Doxorubicin - immunology | Interferon-gamma - pharmacology | Microscopy, Fluorescence | Physiological aspects | Microbial genetics | Phenotype | Genetic aspects | Research | Geometry | Genotype & phenotype | Morphology | Index Medicus | Biological Sciences | Physical Sciences
Journal Article
Oncogene, ISSN 0950-9232, 04/1999, Volume 18, Issue 13, pp. 2241 - 2251
Previous studies have demonstrated a synergistic interaction between rhuMAb HER2 and the cytotoxic drug cisplatin in human breast and ovarian cancer cells. To... 
Chemotherapy | Breast cancer | Synergy | Multiple drug effects analysis | HER-2/neu (c-erbB-2) | HER2/NEU-OVEREXPRESSING METASTATIC BREAST | synergy | GROWTH-FACTOR-RECEPTOR | BIOCHEMISTRY & MOLECULAR BIOLOGY | ANTINEOPLASTIC AGENTS | breast cancer | MONOCLONAL-ANTIBODY | OVARIAN-CANCER | SALIVARY-GLAND | chemotherapy | ENDOMETRIAL CANCER | CELL BIOLOGY | C-ERBB-2 PROTEIN | ONCOLOGY | multiple drug effects analysis | TUMOR NECROSIS FACTOR | GENETICS & HEREDITY | GENE-PRODUCT | Recombinant Proteins - therapeutic use | Doxorubicin - therapeutic use | Adenocarcinoma - pathology | Receptor, ErbB-2 - genetics | Humans | Neoplasm Proteins - immunology | Antibodies, Monoclonal - therapeutic use | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Vinblastine - therapeutic use | Topoisomerase II Inhibitors | Antimetabolites, Antineoplastic - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Receptor, ErbB-2 - immunology | Phosphorylation - drug effects | Neoplasm Proteins - genetics | Receptor, ErbB-2 - biosynthesis | Antibodies, Monoclonal - pharmacology | Etoposide - pharmacology | Combined Modality Therapy | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Drug Synergism | Antimetabolites, Antineoplastic - therapeutic use | Adenocarcinoma - therapy | Antibiotics, Antineoplastic - therapeutic use | Mice, Nude | Cyclophosphamide - pharmacology | Immunization, Passive | Fluorouracil - pharmacology | Mice | Cell Cycle - drug effects | Trastuzumab | Neoplasm Transplantation | Paclitaxel - pharmacology | Antibiotics, Antineoplastic - pharmacology | Antineoplastic Agents, Alkylating - pharmacology | Transplantation, Heterologous | Fluorouracil - antagonists & inhibitors | Cyclophosphamide - therapeutic use | Breast Neoplasms - therapy | Antibodies, Monoclonal, Humanized | Fluorouracil - therapeutic use | Protein Processing, Post-Translational - drug effects | Female | Antineoplastic Agents - pharmacology | Thiotepa - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Neoplasm Proteins - biosynthesis | Etoposide - therapeutic use | Treatment Outcome | Cisplatin - pharmacology | Recombinant Proteins - pharmacology | Paclitaxel - therapeutic use | Neoplasms, Hormone-Dependent - therapy | Animals | Breast Neoplasms - pathology | Neoplasms, Hormone-Dependent - pathology | Vinblastine - pharmacology | Neoplasms, Hormone-Dependent - drug therapy | Doxorubicin - pharmacology | Drug Screening Assays, Antitumor | Index Medicus
Journal Article
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 05/2004, Volume 96, Issue 10, pp. 739 - 749
Background. Trastuzumab, a humanized anti-HER2 antibody, increases the clinical benefit of first-line chemotherapy in patients with metastatic breast cancers... 
TUMOR-CELL LINES | GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | IN-VITRO | PACLITAXEL TAXOL(R) | ONCOLOGY | 1ST-LINE CHEMOTHERAPY | RANDOMIZED-TRIAL | MONOCLONAL-ANTIBODY | CLINICAL PHARMACOKINETICS | DOCETAXEL TAXOTERE(R) | Up-Regulation | Cyclophosphamide - analogs & derivatives | Paclitaxel - pharmacology | Taxoids - pharmacology | Neoplastic Stem Cells - drug effects | Humans | Receptor, ErbB-2 - metabolism | Deoxycytidine - pharmacology | Transplantation, Heterologous | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Breast Neoplasms - metabolism | Antibodies, Monoclonal, Humanized | Vinblastine - analogs & derivatives | Female | Gene Expression Regulation, Neoplastic - drug effects | Receptor, ErbB-2 - drug effects | Disease Models, Animal | Floxuridine - pharmacology | Cell Survival - drug effects | Tumor Stem Cell Assay | Proto-Oncogene Proteins - drug effects | Enzyme-Linked Immunosorbent Assay | Antibodies, Monoclonal - pharmacology | Docetaxel | Breast Neoplasms - drug therapy | DNA, Neoplasm - drug effects | Guanine Nucleotide Exchange Factors | Drug Synergism | Animals | Mice, Nude | Cyclophosphamide - pharmacology | Cell Line, Tumor | Mice | Vinblastine - pharmacology | Carboplatin - pharmacology | Deoxycytidine - analogs & derivatives | Doxorubicin - pharmacology | Trastuzumab | Vinorelbine | Epirubicin - pharmacology | Chemotherapy | Care and treatment | Breast cancer | Research | Health aspects | Drug therapy | Medical treatment | Index Medicus
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 12/2001, Volume 276, Issue 50, pp. 47107 - 47115
Treatment with the DNA topoisomerase inhibitors etoposide, doxorubicin, and camptothecin, and with the alkylating agents cisplatin and melphalan, caused... 
OXYGEN | SUPEROXIDE ANION | BUTHIONINE SULFOXIMINE | INHIBITION | U937 CELLS | NEURONAL DEATH | BIOCHEMISTRY & MOLECULAR BIOLOGY | MITOCHONDRIAL-FUNCTION | SENSITIVITY | HYDROGEN-PEROXIDE | STRESS | Buthionine Sulfoximine - pharmacology | Nucleic Acid Synthesis Inhibitors - pharmacology | Reactive Oxygen Species | Glutathione - metabolism | Alkylating Agents - pharmacology | Humans | Topoisomerase I Inhibitors | Antineoplastic Agents, Alkylating - pharmacology | Immunoblotting | Monocytes - metabolism | Oxygen - metabolism | Antineoplastic Agents - toxicity | Necrosis | Dose-Response Relationship, Drug | Flow Cytometry | Time Factors | U937 Cells | Adenosine Triphosphate - metabolism | Cell Death | Radiation-Protective Agents - pharmacology | Antimetabolites, Antineoplastic - pharmacology | Antineoplastic Agents - pharmacology | Melphalan - pharmacology | Membrane Potentials - drug effects | Enzyme Inhibitors - pharmacology | Hydrogen Peroxide - pharmacology | Etoposide - pharmacology | Spectrometry, Fluorescence | Glutathione - antagonists & inhibitors | Mitochondria - metabolism | Antioxidants - pharmacology | Cisplatin - pharmacology | Hypoxia | Antineoplastic Agents, Phytogenic - pharmacology | Camptothecin - pharmacology | Dose-Response Relationship, Radiation | Doxorubicin - pharmacology | Apoptosis | butylated hydroxyanisole | melphelan | N-Acetyl-L-cysteine | cisplatin | Index Medicus
Journal Article